Received Apr 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 3 | B0005 | IM / RA |
No adverse event reported. Reporting per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
chronic pain, COPD, cigarette burn on foot
chronic diastolic heart failure, chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity, fetal and neonatal cutaneous hemorrhage, myalgia and myostitis, scoliosis and kyphoscoliosis, carpal tunnel syndrome, brachial neuritis or radiculitis, restless legs, degeneration of lumbar intervertebral disc, chronic pain, thoracic or lumbosacral neuritis or radiculitis, allergic rhinitis, GERD, asthma, COPD, constipation, urinary incontinence, bipolar disorder, alcohol use disorder, other stimulant abuse, PTSD, disorder of breast, bariatric surgery, insomnia
acetaminophen, cyclobenzaprine, furosemide, lidocaine, naloxone, eliquis, trazodone, naltrexone, multivitamin, aspirin, loperamide, senna, cholecalciferol, fluticasone, hydroxyzine, loratadine, ondansetron, potassium chloride, calcium antac
codeine, pollen
N/A